2-Bromomescaline

2-Bromomescaline (2-Br-M) is a derivative of the phenethylamine hallucinogen mescaline which has an unusual 2-bromo substitution. It is an agonist for serotonin receptors, with a binding affinity of 215 nM at 5-HT_1A, 513 nM at 5-HT_2A and 379 nM at 5-HT_2C, so while it is around ten times more tightly binding than mescaline at 5-HT_1A and 5-HT_2A receptors, it is over twenty times more potent at 5-HT_2C. It has been reported as a designer drug, first identified in Austria in January 2023.